Nebenwirkungen · Flixabi
Flixabi 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 19
HOS-222773 · Präparat HOS-217086
In an exploratory clinical study involving patients with moderate to severe COPD who were either current smokers or ex-smokers, 157 adult patients were treated with infliximab at doses similar to those used in rheumatoid arthritis and Crohn’s disease. Nine of these patients developed malignancies, including 1 lymphoma. The median duration of follow-up was 0.8 years (incidence 5.7% [95% CI 2.65%-10.6%]. There was one reported malignancy amongst 77 control patients (median duration of follow-up 0.8 years; incidence 1.3% [95% CI 0.03%-7.0%]). The majority of the malignancies developed in the lung or head and neck.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T12:15:00Z · SHA-256 01df900501649a0c225dc84d8f07b05b21b1d4deab3ad6c2da84a4b6879f8b57 · Passage f0198087b1dece332772096f290bec9ce06bffb62f0cb8347930418cbb8d237b · Zeichen 19445–20063 im Abschnitt